Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the …
BA Ference, HN Ginsberg, I Graham… - European heart …, 2017 - academic.oup.com
Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs)
cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed …
cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed …
Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series
BA Ference, I Graham, L Tokgozoglu… - Journal of the American …, 2018 - jacc.org
People who maintain ideal cardiovascular heath have a low lifetime risk of cardiovascular
disease. Therefore, encouraging people to achieve ideal cardiovascular health represents …
disease. Therefore, encouraging people to achieve ideal cardiovascular health represents …
Артериальная гипертензия у взрослых. Клинические рекомендации 2020
ЖД Кобалава, АО Конради, СВ Недогода… - Российский …, 2020 - cyberleninka.ru
Члены Рабочей группы: Арутюнов ГП, Баранова ЕИ, Барбараш ОЛ, Бойцов СА,
Вавилова ТВ, Виллевальде СВ, Галявич АС, Глезер МГ, Гринева ЕН, Гринштейн ЮИ …
Вавилова ТВ, Виллевальде СВ, Галявич АС, Глезер МГ, Гринева ЕН, Гринштейн ЮИ …
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE* 3Leiden …
C Landlinger, MG Pouwer, C Juno… - European heart …, 2017 - academic.oup.com
Aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising
therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 …
therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 …
Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol
GR Thompson, DJ Blom, AD Marais… - European Heart …, 2018 - academic.oup.com
Aims Homozygous familial hypercholesterolaemia (FH) is a rare inherited disorder
characterized by extreme hypercholesterolaemia from birth, accelerated atherosclerosis …
characterized by extreme hypercholesterolaemia from birth, accelerated atherosclerosis …
Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high-or moderate-intensity statins
KM Fox, MH Tai, K Kostev, M Hatz, Y Qian… - Clinical Research in …, 2018 - Springer
Background European clinical guidelines recommend a low-density lipoprotein cholesterol
(LDL-C) goal of< 70 mg/dL. Statin use varies and past studies suggest low rates of real …
(LDL-C) goal of< 70 mg/dL. Statin use varies and past studies suggest low rates of real …
Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary …
Aims The total cholesterol (TC)/high-density lipoprotein (HDL) cholesterol ratio may carry
additional information not available in more commonly used single cholesterol measures …
additional information not available in more commonly used single cholesterol measures …
[HTML][HTML] Течение артериальной гипертензии у жителей засушливого региона
Г Самиева, У Нарзулаева, У Самиев - Каталог монографий, 2023 - inlibrary.uz
Аннотация Ушбу монография иссик иклим шароитида гипертония касаллигининг
бошлангич боскичларида гемореологик ва дислипидемии бузилишлар ва уларни …
бошлангич боскичларида гемореологик ва дислипидемии бузилишлар ва уларни …
Predicting cardiovascular outcomes by baseline lipoprotein (a) concentrations: a large cohort and long‐term follow‐up study on real‐world patients receiving …
HH Liu, YX Cao, JL Jin, HW Zhang, QI Hua… - Journal of the …, 2020 - Am Heart Assoc
Background Although several studies have indicated that lipoprotein (a) is a useful
prognostic predictor for patients following percutaneous coronary intervention (PCI) …
prognostic predictor for patients following percutaneous coronary intervention (PCI) …
PCSK9 inhibitors and cardiovascular outcomes
D Steffens, P Bramlage, C Scheeff… - Expert opinion on …, 2020 - Taylor & Francis
Introduction: Dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C),
is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), and lipid-lowering …
is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), and lipid-lowering …